Question to the Department of Health and Social Care:

To ask Her Majesty's Government what assessment they have made of (1) clinical trial data showing the effectiveness of Ivermectin to treat COVID-19, and (2) the urgency of approving new treatments for COVID-19; and when they expect the Medicines and Healthcare products Regulatory Agency to come to a decision on approving Ivermectin for use in the UK.

Evidence from clinical trials of ivermectin as a treatment for COVID-19 is inconclusive at this stage. We will continue to monitor the data from clinical trials continuing worldwide, including the Government-funded PRINCIPLE trial, to expand the evidence base for ivermectin. We recognise the need to make treatments for COVID-19 available to patients once proven as safe and effective. The RAPID-C19 group was established to accelerate the process between the completion of clinical trials and patient access. Ivermectin will be considered for marketing authorisation in the United Kingdom as a treatment for COVID-19 should an application be received from a manufacturer.